nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—PTK6—uterine cervix—vaginal cancer	0.0112	0.0124	CbGeAlD
Vandetanib—PTK6—urethra—vaginal cancer	0.0103	0.0114	CbGeAlD
Vandetanib—PTK6—mammalian vulva—vaginal cancer	0.00979	0.0109	CbGeAlD
Vandetanib—LTK—female reproductive system—vaginal cancer	0.00875	0.00971	CbGeAlD
Vandetanib—BMPR1B—epithelium—vaginal cancer	0.00856	0.0095	CbGeAlD
Vandetanib—PTK6—female reproductive system—vaginal cancer	0.00839	0.00931	CbGeAlD
Vandetanib—PTK6—female gonad—vaginal cancer	0.00763	0.00847	CbGeAlD
Vandetanib—PTK6—vagina—vaginal cancer	0.00759	0.00842	CbGeAlD
Vandetanib—BMPR1B—uterus—vaginal cancer	0.00707	0.00785	CbGeAlD
Vandetanib—EPHA6—female reproductive system—vaginal cancer	0.00699	0.00776	CbGeAlD
Vandetanib—PLK4—female reproductive system—vaginal cancer	0.00691	0.00767	CbGeAlD
Vandetanib—EGFR—uterine cervix—vaginal cancer	0.00686	0.00762	CbGeAlD
Vandetanib—FLT4—epithelium—vaginal cancer	0.00674	0.00749	CbGeAlD
Vandetanib—RIPK2—epithelium—vaginal cancer	0.00671	0.00745	CbGeAlD
Vandetanib—RIPK2—uterine cervix—vaginal cancer	0.00665	0.00738	CbGeAlD
Vandetanib—VEGFA—uterine cervix—vaginal cancer	0.00663	0.00736	CbGeAlD
Vandetanib—FMO1—uterine cervix—vaginal cancer	0.0066	0.00732	CbGeAlD
Vandetanib—IRAK4—uterine cervix—vaginal cancer	0.00649	0.00721	CbGeAlD
Vandetanib—TYRO3—female reproductive system—vaginal cancer	0.00649	0.0072	CbGeAlD
Vandetanib—ERBB3—epithelium—vaginal cancer	0.00642	0.00713	CbGeAlD
Vandetanib—ERBB3—uterine cervix—vaginal cancer	0.00637	0.00707	CbGeAlD
Vandetanib—BMPR1B—female reproductive system—vaginal cancer	0.00636	0.00706	CbGeAlD
Vandetanib—MAP3K19—female reproductive system—vaginal cancer	0.00636	0.00706	CbGeAlD
Vandetanib—RIPK2—urethra—vaginal cancer	0.00611	0.00679	CbGeAlD
Vandetanib—VEGFA—urethra—vaginal cancer	0.0061	0.00677	CbGeAlD
Vandetanib—FMO1—urethra—vaginal cancer	0.00606	0.00673	CbGeAlD
Vandetanib—RIPK2—endometrium—vaginal cancer	0.00602	0.00668	CbGeAlD
Vandetanib—EGFR—mammalian vulva—vaginal cancer	0.006	0.00666	CbGeAlD
Vandetanib—VEGFA—endometrium—vaginal cancer	0.006	0.00666	CbGeAlD
Vandetanib—MKNK1—uterine cervix—vaginal cancer	0.00598	0.00664	CbGeAlD
Vandetanib—IRAK4—urethra—vaginal cancer	0.00597	0.00663	CbGeAlD
Vandetanib—FMO1—endometrium—vaginal cancer	0.00597	0.00662	CbGeAlD
Vandetanib—RET—epithelium—vaginal cancer	0.00595	0.00661	CbGeAlD
Vandetanib—LCK—uterine cervix—vaginal cancer	0.0059	0.00655	CbGeAlD
Vandetanib—TYRO3—female gonad—vaginal cancer	0.0059	0.00655	CbGeAlD
Vandetanib—AXL—uterine cervix—vaginal cancer	0.00588	0.00653	CbGeAlD
Vandetanib—IRAK4—endometrium—vaginal cancer	0.00587	0.00652	CbGeAlD
Vandetanib—EPHA5—vagina—vaginal cancer	0.00587	0.00651	CbGeAlD
Vandetanib—VEGFA—mammalian vulva—vaginal cancer	0.0058	0.00644	CbGeAlD
Vandetanib—BMPR1B—female gonad—vaginal cancer	0.00578	0.00642	CbGeAlD
Vandetanib—FMO1—mammalian vulva—vaginal cancer	0.00577	0.00641	CbGeAlD
Vandetanib—EGFR—uterus—vaginal cancer	0.00572	0.00635	CbGeAlD
Vandetanib—IRAK4—mammalian vulva—vaginal cancer	0.00568	0.00631	CbGeAlD
Vandetanib—SLK—uterine cervix—vaginal cancer	0.00566	0.00628	CbGeAlD
Vandetanib—VEGFA—uterus—vaginal cancer	0.00553	0.00614	CbGeAlD
Vandetanib—FLT3—female reproductive system—vaginal cancer	0.00552	0.00612	CbGeAlD
Vandetanib—FYN—uterine cervix—vaginal cancer	0.0055	0.00611	CbGeAlD
Vandetanib—MKNK1—urethra—vaginal cancer	0.00549	0.0061	CbGeAlD
Vandetanib—LCK—urethra—vaginal cancer	0.00543	0.00602	CbGeAlD
Vandetanib—FGR—urethra—vaginal cancer	0.00543	0.00602	CbGeAlD
Vandetanib—TEK—epithelium—vaginal cancer	0.00542	0.00602	CbGeAlD
Vandetanib—MKNK1—endometrium—vaginal cancer	0.00541	0.006	CbGeAlD
Vandetanib—STK35—female reproductive system—vaginal cancer	0.0054	0.006	CbGeAlD
Vandetanib—AXL—urethra—vaginal cancer	0.0054	0.006	CbGeAlD
Vandetanib—MAP4K5—uterine cervix—vaginal cancer	0.00538	0.00597	CbGeAlD
Vandetanib—FGR—endometrium—vaginal cancer	0.00534	0.00593	CbGeAlD
Vandetanib—AXL—endometrium—vaginal cancer	0.00532	0.0059	CbGeAlD
Vandetanib—ERBB3—uterus—vaginal cancer	0.00531	0.00589	CbGeAlD
Vandetanib—MKNK1—mammalian vulva—vaginal cancer	0.00523	0.00581	CbGeAlD
Vandetanib—SLK—urethra—vaginal cancer	0.0052	0.00577	CbGeAlD
Vandetanib—LCK—mammalian vulva—vaginal cancer	0.00517	0.00573	CbGeAlD
Vandetanib—FGR—mammalian vulva—vaginal cancer	0.00517	0.00573	CbGeAlD
Vandetanib—AXL—mammalian vulva—vaginal cancer	0.00514	0.00571	CbGeAlD
Vandetanib—EPHB6—uterine cervix—vaginal cancer	0.00514	0.00571	CbGeAlD
Vandetanib—SLK—endometrium—vaginal cancer	0.00512	0.00568	CbGeAlD
Vandetanib—FYN—urethra—vaginal cancer	0.00506	0.00561	CbGeAlD
Vandetanib—FLT3—female gonad—vaginal cancer	0.00502	0.00557	CbGeAlD
Vandetanib—FLT4—female reproductive system—vaginal cancer	0.00501	0.00556	CbGeAlD
Vandetanib—FMO3—mammalian vulva—vaginal cancer	0.00499	0.00554	CbGeAlD
Vandetanib—RIPK2—female reproductive system—vaginal cancer	0.00498	0.00553	CbGeAlD
Vandetanib—FYN—endometrium—vaginal cancer	0.00498	0.00553	CbGeAlD
Vandetanib—YES1—uterine cervix—vaginal cancer	0.00497	0.00551	CbGeAlD
Vandetanib—SLK—mammalian vulva—vaginal cancer	0.00495	0.0055	CbGeAlD
Vandetanib—MAP4K5—urethra—vaginal cancer	0.00494	0.00549	CbGeAlD
Vandetanib—TEK—urethra—vaginal cancer	0.00494	0.00549	CbGeAlD
Vandetanib—STK10—uterine cervix—vaginal cancer	0.00492	0.00546	CbGeAlD
Vandetanib—LCK—uterus—vaginal cancer	0.00492	0.00546	CbGeAlD
Vandetanib—STK35—female gonad—vaginal cancer	0.00492	0.00546	CbGeAlD
Vandetanib—AXL—uterus—vaginal cancer	0.0049	0.00544	CbGeAlD
Vandetanib—STK35—vagina—vaginal cancer	0.00489	0.00543	CbGeAlD
Vandetanib—TEK—endometrium—vaginal cancer	0.00486	0.0054	CbGeAlD
Vandetanib—MAP4K5—endometrium—vaginal cancer	0.00486	0.0054	CbGeAlD
Vandetanib—SRC—epithelium—vaginal cancer	0.00482	0.00535	CbGeAlD
Vandetanib—FYN—mammalian vulva—vaginal cancer	0.00481	0.00535	CbGeAlD
Vandetanib—ABL2—female gonad—vaginal cancer	0.00479	0.00532	CbGeAlD
Vandetanib—SRC—uterine cervix—vaginal cancer	0.00478	0.0053	CbGeAlD
Vandetanib—ERBB3—female reproductive system—vaginal cancer	0.00477	0.0053	CbGeAlD
Vandetanib—ABL2—vagina—vaginal cancer	0.00476	0.00529	CbGeAlD
Vandetanib—EPHB6—urethra—vaginal cancer	0.00472	0.00524	CbGeAlD
Vandetanib—SLK—uterus—vaginal cancer	0.00472	0.00524	CbGeAlD
Vandetanib—MAP4K5—mammalian vulva—vaginal cancer	0.00471	0.00522	CbGeAlD
Vandetanib—EGFR—female gonad—vaginal cancer	0.00468	0.00519	CbGeAlD
Vandetanib—EPHB6—endometrium—vaginal cancer	0.00465	0.00516	CbGeAlD
Vandetanib—FYN—uterus—vaginal cancer	0.00459	0.00509	CbGeAlD
Vandetanib—YES1—urethra—vaginal cancer	0.00456	0.00507	CbGeAlD
Vandetanib—FLT4—female gonad—vaginal cancer	0.00456	0.00506	CbGeAlD
Vandetanib—RIPK2—female gonad—vaginal cancer	0.00453	0.00503	CbGeAlD
Vandetanib—VEGFA—female gonad—vaginal cancer	0.00452	0.00502	CbGeAlD
Vandetanib—RIPK2—vagina—vaginal cancer	0.00451	0.005	CbGeAlD
Vandetanib—FMO1—female gonad—vaginal cancer	0.0045	0.00499	CbGeAlD
Vandetanib—EPHB6—mammalian vulva—vaginal cancer	0.0045	0.00499	CbGeAlD
Vandetanib—VEGFA—vagina—vaginal cancer	0.00449	0.00499	CbGeAlD
Vandetanib—YES1—endometrium—vaginal cancer	0.00449	0.00499	CbGeAlD
Vandetanib—MAP4K5—uterus—vaginal cancer	0.00448	0.00498	CbGeAlD
Vandetanib—TEK—uterus—vaginal cancer	0.00448	0.00498	CbGeAlD
Vandetanib—MKNK1—female reproductive system—vaginal cancer	0.00448	0.00497	CbGeAlD
Vandetanib—FMO1—vagina—vaginal cancer	0.00447	0.00496	CbGeAlD
Vandetanib—KDR—epithelium—vaginal cancer	0.00443	0.00492	CbGeAlD
Vandetanib—IRAK4—female gonad—vaginal cancer	0.00443	0.00492	CbGeAlD
Vandetanib—FGR—female reproductive system—vaginal cancer	0.00442	0.00491	CbGeAlD
Vandetanib—AXL—female reproductive system—vaginal cancer	0.00441	0.00489	CbGeAlD
Vandetanib—IRAK4—vagina—vaginal cancer	0.0044	0.00489	CbGeAlD
Vandetanib—MAP2K5—uterine cervix—vaginal cancer	0.0044	0.00488	CbGeAlD
Vandetanib—KDR—uterine cervix—vaginal cancer	0.0044	0.00488	CbGeAlD
Vandetanib—YES1—mammalian vulva—vaginal cancer	0.00435	0.00482	CbGeAlD
Vandetanib—ERBB3—female gonad—vaginal cancer	0.00434	0.00482	CbGeAlD
Vandetanib—STK10—mammalian vulva—vaginal cancer	0.00431	0.00478	CbGeAlD
Vandetanib—YES1—uterus—vaginal cancer	0.00414	0.0046	CbGeAlD
Vandetanib—FYN—female reproductive system—vaginal cancer	0.00412	0.00458	CbGeAlD
Vandetanib—STK10—uterus—vaginal cancer	0.0041	0.00455	CbGeAlD
Vandetanib—MKNK1—female gonad—vaginal cancer	0.00407	0.00452	CbGeAlD
Vandetanib—MKNK1—vagina—vaginal cancer	0.00405	0.0045	CbGeAlD
Vandetanib—MAP2K5—urethra—vaginal cancer	0.00404	0.00448	CbGeAlD
Vandetanib—KDR—urethra—vaginal cancer	0.00404	0.00448	CbGeAlD
Vandetanib—MAP4K5—female reproductive system—vaginal cancer	0.00403	0.00447	CbGeAlD
Vandetanib—TEK—female reproductive system—vaginal cancer	0.00403	0.00447	CbGeAlD
Vandetanib—FGR—female gonad—vaginal cancer	0.00403	0.00447	CbGeAlD
Vandetanib—LCK—female gonad—vaginal cancer	0.00403	0.00447	CbGeAlD
Vandetanib—AXL—female gonad—vaginal cancer	0.00401	0.00445	CbGeAlD
Vandetanib—FGR—vagina—vaginal cancer	0.004	0.00444	CbGeAlD
Vandetanib—LCK—vagina—vaginal cancer	0.004	0.00444	CbGeAlD
Vandetanib—AXL—vagina—vaginal cancer	0.00398	0.00442	CbGeAlD
Vandetanib—MAP2K5—endometrium—vaginal cancer	0.00398	0.00441	CbGeAlD
Vandetanib—KDR—endometrium—vaginal cancer	0.00398	0.00441	CbGeAlD
Vandetanib—FMO3—vagina—vaginal cancer	0.00386	0.00429	CbGeAlD
Vandetanib—SLK—female gonad—vaginal cancer	0.00386	0.00428	CbGeAlD
Vandetanib—KDR—mammalian vulva—vaginal cancer	0.00385	0.00427	CbGeAlD
Vandetanib—MAP2K5—mammalian vulva—vaginal cancer	0.00385	0.00427	CbGeAlD
Vandetanib—PDGFRB—epithelium—vaginal cancer	0.00384	0.00426	CbGeAlD
Vandetanib—SLK—vagina—vaginal cancer	0.00384	0.00426	CbGeAlD
Vandetanib—PDGFRB—uterine cervix—vaginal cancer	0.0038	0.00422	CbGeAlD
Vandetanib—FYN—female gonad—vaginal cancer	0.00375	0.00417	CbGeAlD
Vandetanib—FYN—vagina—vaginal cancer	0.00373	0.00414	CbGeAlD
Vandetanib—YES1—female reproductive system—vaginal cancer	0.00372	0.00413	CbGeAlD
Vandetanib—STK10—female reproductive system—vaginal cancer	0.00369	0.00409	CbGeAlD
Vandetanib—TEK—female gonad—vaginal cancer	0.00367	0.00407	CbGeAlD
Vandetanib—MAP4K5—female gonad—vaginal cancer	0.00367	0.00407	CbGeAlD
Vandetanib—KDR—uterus—vaginal cancer	0.00366	0.00407	CbGeAlD
Vandetanib—MAP4K5—vagina—vaginal cancer	0.00364	0.00405	CbGeAlD
Vandetanib—SRC—female reproductive system—vaginal cancer	0.00358	0.00397	CbGeAlD
Vandetanib—EPHB6—female gonad—vaginal cancer	0.0035	0.00389	CbGeAlD
Vandetanib—PDGFRB—urethra—vaginal cancer	0.0035	0.00388	CbGeAlD
Vandetanib—EPHB6—vagina—vaginal cancer	0.00348	0.00387	CbGeAlD
Vandetanib—PDGFRB—endometrium—vaginal cancer	0.00344	0.00382	CbGeAlD
Vandetanib—IRAK4—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00343	0.0346	CbGpPWpGaD
Vandetanib—ABL1—uterine cervix—vaginal cancer	0.00339	0.00376	CbGeAlD
Vandetanib—YES1—female gonad—vaginal cancer	0.00339	0.00376	CbGeAlD
Vandetanib—YES1—vagina—vaginal cancer	0.00337	0.00374	CbGeAlD
Vandetanib—STK10—female gonad—vaginal cancer	0.00336	0.00373	CbGeAlD
Vandetanib—STK10—vagina—vaginal cancer	0.00334	0.0037	CbGeAlD
Vandetanib—PDGFRB—mammalian vulva—vaginal cancer	0.00333	0.0037	CbGeAlD
Vandetanib—KDR—female reproductive system—vaginal cancer	0.00329	0.00366	CbGeAlD
Vandetanib—MAP2K5—female reproductive system—vaginal cancer	0.00329	0.00366	CbGeAlD
Vandetanib—SRC—female gonad—vaginal cancer	0.00326	0.00362	CbGeAlD
Vandetanib—ORM1—endometrium—vaginal cancer	0.00323	0.00358	CbGeAlD
Vandetanib—PDGFRB—uterus—vaginal cancer	0.00317	0.00352	CbGeAlD
Vandetanib—ABL1—urethra—vaginal cancer	0.00312	0.00346	CbGeAlD
Vandetanib—RIPK2—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00311	0.0313	CbGpPWpGaD
Vandetanib—ABL1—endometrium—vaginal cancer	0.00307	0.0034	CbGeAlD
Vandetanib—MAP2K5—female gonad—vaginal cancer	0.003	0.00333	CbGeAlD
Vandetanib—KDR—female gonad—vaginal cancer	0.003	0.00333	CbGeAlD
Vandetanib—KDR—vagina—vaginal cancer	0.00298	0.00331	CbGeAlD
Vandetanib—MAP2K5—vagina—vaginal cancer	0.00298	0.00331	CbGeAlD
Vandetanib—ABL1—mammalian vulva—vaginal cancer	0.00297	0.00329	CbGeAlD
Vandetanib—IRAK4—Toll-like Receptor Signaling Pathway—IFNA1—vaginal cancer	0.00288	0.029	CbGpPWpGaD
Vandetanib—PDGFRB—female reproductive system—vaginal cancer	0.00285	0.00316	CbGeAlD
Vandetanib—ABL1—uterus—vaginal cancer	0.00283	0.00314	CbGeAlD
Vandetanib—ORM1—female reproductive system—vaginal cancer	0.00267	0.00297	CbGeAlD
Vandetanib—PDGFRB—female gonad—vaginal cancer	0.00259	0.00288	CbGeAlD
Vandetanib—ABCC1—uterine cervix—vaginal cancer	0.00258	0.00287	CbGeAlD
Vandetanib—PDGFRB—vagina—vaginal cancer	0.00258	0.00286	CbGeAlD
Vandetanib—ABL1—female reproductive system—vaginal cancer	0.00254	0.00282	CbGeAlD
Vandetanib—TEK—SHP2 signaling—IL2—vaginal cancer	0.00252	0.0254	CbGpPWpGaD
Vandetanib—YES1—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.0024	0.0242	CbGpPWpGaD
Vandetanib—ABCC1—urethra—vaginal cancer	0.00237	0.00264	CbGeAlD
Vandetanib—ABCC1—endometrium—vaginal cancer	0.00234	0.00259	CbGeAlD
Vandetanib—ABL1—female gonad—vaginal cancer	0.00231	0.00257	CbGeAlD
Vandetanib—ABL1—vagina—vaginal cancer	0.0023	0.00255	CbGeAlD
Vandetanib—ABCC1—mammalian vulva—vaginal cancer	0.00226	0.00251	CbGeAlD
Vandetanib—IRAK4—Regulation of toll-like receptor signaling pathway—IFNA1—vaginal cancer	0.00225	0.0227	CbGpPWpGaD
Vandetanib—ABCC1—uterus—vaginal cancer	0.00215	0.00239	CbGeAlD
Vandetanib—ABCG2—uterine cervix—vaginal cancer	0.00214	0.00237	CbGeAlD
Vandetanib—ABCG2—urethra—vaginal cancer	0.00197	0.00218	CbGeAlD
Vandetanib—ABCG2—endometrium—vaginal cancer	0.00193	0.00215	CbGeAlD
Vandetanib—ABCG2—mammalian vulva—vaginal cancer	0.00187	0.00208	CbGeAlD
Vandetanib—LYN—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00179	0.0181	CbGpPWpGaD
Vandetanib—ABCG2—uterus—vaginal cancer	0.00178	0.00198	CbGeAlD
Vandetanib—FYN—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00176	0.0178	CbGpPWpGaD
Vandetanib—ABCC1—female gonad—vaginal cancer	0.00176	0.00195	CbGeAlD
Vandetanib—ABCC1—vagina—vaginal cancer	0.00175	0.00194	CbGeAlD
Vandetanib—FYN—T-Cell Receptor and Co-stimulatory Signaling—IL2—vaginal cancer	0.00167	0.0169	CbGpPWpGaD
Vandetanib—RIPK2—IL12-mediated signaling events—IL2—vaginal cancer	0.00165	0.0166	CbGpPWpGaD
Vandetanib—YES1—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.00163	0.0165	CbGpPWpGaD
Vandetanib—KDR—SHP2 signaling—IL2—vaginal cancer	0.00151	0.0152	CbGpPWpGaD
Vandetanib—LCK—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00147	0.0148	CbGpPWpGaD
Vandetanib—ABCG2—female gonad—vaginal cancer	0.00146	0.00162	CbGeAlD
Vandetanib—ABCG2—vagina—vaginal cancer	0.00145	0.00161	CbGeAlD
Vandetanib—LCK—T-Cell Receptor and Co-stimulatory Signaling—IL2—vaginal cancer	0.00139	0.014	CbGpPWpGaD
Vandetanib—LCK—IL2 signaling events mediated by STAT5—IL2—vaginal cancer	0.00136	0.0137	CbGpPWpGaD
Vandetanib—LCK—Inflammatory Response Pathway—IL2—vaginal cancer	0.00136	0.0137	CbGpPWpGaD
Vandetanib—VEGFA—SHP2 signaling—IL2—vaginal cancer	0.00136	0.0137	CbGpPWpGaD
Vandetanib—LYN—IL-5 Signaling Pathway—IL2—vaginal cancer	0.00131	0.0132	CbGpPWpGaD
Vandetanib—IRAK4—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00128	0.0129	CbGpPWpGaD
Vandetanib—FYN—IL-2 Signaling Pathway—IL2—vaginal cancer	0.00124	0.0125	CbGpPWpGaD
Vandetanib—LYN—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.00122	0.0123	CbGpPWpGaD
Vandetanib—FYN—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.0012	0.0121	CbGpPWpGaD
Vandetanib—ABL1—Factors involved in megakaryocyte development and platelet production—IFNA1—vaginal cancer	0.00119	0.012	CbGpPWpGaD
Vandetanib—RIPK2—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00116	0.0117	CbGpPWpGaD
Vandetanib—LCK—IL2 signaling events mediated by PI3K—IL2—vaginal cancer	0.00115	0.0116	CbGpPWpGaD
Vandetanib—IRAK4—Signaling by Interleukins—IL2—vaginal cancer	0.00114	0.0115	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—EIF4A3—vaginal cancer	0.00112	0.0113	CbGpPWpGaD
Vandetanib—LYN—GPVI-mediated activation cascade—IL2—vaginal cancer	0.00112	0.0113	CbGpPWpGaD
Vandetanib—CYP3A4—female reproductive system—vaginal cancer	0.00112	0.00124	CbGeAlD
Vandetanib—FYN—GPVI-mediated activation cascade—IL2—vaginal cancer	0.0011	0.0111	CbGpPWpGaD
Vandetanib—TEK—Hemostasis—IFNA1—vaginal cancer	0.00108	0.0108	CbGpPWpGaD
Vandetanib—VEGFA—Allograft Rejection—IL2—vaginal cancer	0.00106	0.0107	CbGpPWpGaD
Vandetanib—LCK—IL-2 Signaling Pathway—IL2—vaginal cancer	0.00104	0.0104	CbGpPWpGaD
Vandetanib—RIPK2—Signaling by Interleukins—IL2—vaginal cancer	0.00103	0.0104	CbGpPWpGaD
Vandetanib—FYN—IL2-mediated signaling events—IL2—vaginal cancer	0.00102	0.0103	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—EIF4A3—vaginal cancer	0.00101	0.0102	CbGpPWpGaD
Vandetanib—EGFR—Aryl Hydrocarbon Receptor Pathway—IL2—vaginal cancer	0.001	0.0101	CbGpPWpGaD
Vandetanib—PDGFRB—SHP2 signaling—IL2—vaginal cancer	0.000997	0.01	CbGpPWpGaD
Vandetanib—BLK—Immune System—EIF4A3—vaginal cancer	0.000976	0.00983	CbGpPWpGaD
Vandetanib—FGR—Immune System—EIF4A3—vaginal cancer	0.000973	0.0098	CbGpPWpGaD
Vandetanib—LCK—Interleukin-2 signaling—IL2—vaginal cancer	0.000947	0.00954	CbGpPWpGaD
Vandetanib—LCK—GPVI-mediated activation cascade—IL2—vaginal cancer	0.000916	0.00923	CbGpPWpGaD
Vandetanib—YES1—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000899	0.00906	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—EIF4A3—vaginal cancer	0.000894	0.00901	CbGpPWpGaD
Vandetanib—ABL1—Regulation of Telomerase—IL2—vaginal cancer	0.000856	0.00862	CbGpPWpGaD
Vandetanib—SRC—Aryl Hydrocarbon Receptor Pathway—IL2—vaginal cancer	0.000853	0.00859	CbGpPWpGaD
Vandetanib—LCK—IL2-mediated signaling events—IL2—vaginal cancer	0.000847	0.00854	CbGpPWpGaD
Vandetanib—EGFR—SHP2 signaling—IL2—vaginal cancer	0.00083	0.00837	CbGpPWpGaD
Vandetanib—LCK—SHP2 signaling—IL2—vaginal cancer	0.0008	0.00806	CbGpPWpGaD
Vandetanib—YES1—Signaling by Interleukins—IL2—vaginal cancer	0.000796	0.00802	CbGpPWpGaD
Vandetanib—YES1—Immune System—EIF4A3—vaginal cancer	0.000785	0.00791	CbGpPWpGaD
Vandetanib—LCK—IL12-mediated signaling events—IL2—vaginal cancer	0.000779	0.00785	CbGpPWpGaD
Vandetanib—EGFR—Regulation of Telomerase—IL2—vaginal cancer	0.000731	0.00737	CbGpPWpGaD
Vandetanib—IRAK4—Innate Immune System—IFNA1—vaginal cancer	0.00072	0.00726	CbGpPWpGaD
Vandetanib—FGR—Hemostasis—IFNA1—vaginal cancer	0.000693	0.00699	CbGpPWpGaD
Vandetanib—LYN—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00067	0.00675	CbGpPWpGaD
Vandetanib—FYN—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00066	0.00665	CbGpPWpGaD
Vandetanib—RIPK2—Innate Immune System—IFNA1—vaginal cancer	0.000651	0.00656	CbGpPWpGaD
Vandetanib—FGR—Innate Immune System—IFNA1—vaginal cancer	0.000624	0.00629	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—EIF4A3—vaginal cancer	0.000598	0.00602	CbGpPWpGaD
Vandetanib—LYN—Signaling by Interleukins—IL2—vaginal cancer	0.000594	0.00598	CbGpPWpGaD
Vandetanib—LYN—Immune System—EIF4A3—vaginal cancer	0.000585	0.0059	CbGpPWpGaD
Vandetanib—FYN—Signaling by Interleukins—IL2—vaginal cancer	0.000584	0.00589	CbGpPWpGaD
Vandetanib—ABL1—Immune System—EIF4A3—vaginal cancer	0.000583	0.00587	CbGpPWpGaD
Vandetanib—VEGFA—Hemostasis—IFNA1—vaginal cancer	0.000579	0.00584	CbGpPWpGaD
Vandetanib—FYN—Immune System—EIF4A3—vaginal cancer	0.000576	0.00581	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—IFNA1—vaginal cancer	0.000574	0.00578	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—IFNA1—vaginal cancer	0.00056	0.00564	CbGpPWpGaD
Vandetanib—LCK—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000549	0.00553	CbGpPWpGaD
Vandetanib—IRAK4—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000531	0.00535	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—IFNA1—vaginal cancer	0.000504	0.00508	CbGpPWpGaD
Vandetanib—EGFR—Immune System—EIF4A3—vaginal cancer	0.000498	0.00502	CbGpPWpGaD
Vandetanib—LCK—Signaling by Interleukins—IL2—vaginal cancer	0.000487	0.0049	CbGpPWpGaD
Vandetanib—RIPK2—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.00048	0.00484	CbGpPWpGaD
Vandetanib—LCK—Immune System—EIF4A3—vaginal cancer	0.00048	0.00483	CbGpPWpGaD
Vandetanib—EGFR—Spinal Cord Injury—IL2—vaginal cancer	0.00047	0.00474	CbGpPWpGaD
Vandetanib—VEGFA—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000465	0.00468	CbGpPWpGaD
Vandetanib—TEK—Hemostasis—IL2—vaginal cancer	0.000445	0.00448	CbGpPWpGaD
Vandetanib—ALB—Folate Metabolism—IL2—vaginal cancer	0.000431	0.00435	CbGpPWpGaD
Vandetanib—SRC—Immune System—EIF4A3—vaginal cancer	0.000425	0.00428	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—IFNA1—vaginal cancer	0.000419	0.00423	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—IFNA1—vaginal cancer	0.000417	0.00421	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—IFNA1—vaginal cancer	0.000415	0.00419	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—IFNA1—vaginal cancer	0.000411	0.00414	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—IFNA1—vaginal cancer	0.000384	0.00387	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—IFNA1—vaginal cancer	0.000379	0.00382	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—IFNA1—vaginal cancer	0.000376	0.00379	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—IFNA1—vaginal cancer	0.000374	0.00377	CbGpPWpGaD
Vandetanib—YES1—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000372	0.00374	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—IFNA1—vaginal cancer	0.00037	0.00373	CbGpPWpGaD
Vandetanib—BLK—Immune System—IFNA1—vaginal cancer	0.000365	0.00368	CbGpPWpGaD
Vandetanib—FGR—Immune System—IFNA1—vaginal cancer	0.000364	0.00366	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—IFNA1—vaginal cancer	0.000342	0.00345	CbGpPWpGaD
Vandetanib—LYN—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000335	0.00337	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IFNA1—vaginal cancer	0.000334	0.00337	CbGpPWpGaD
Vandetanib—FYN—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.00033	0.00332	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—IFNA1—vaginal cancer	0.00032	0.00322	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—IFNA1—vaginal cancer	0.000308	0.0031	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—IFNA1—vaginal cancer	0.000303	0.00305	CbGpPWpGaD
Vandetanib—YES1—Immune System—IFNA1—vaginal cancer	0.000293	0.00296	CbGpPWpGaD
Vandetanib—FGR—Hemostasis—IL2—vaginal cancer	0.000287	0.00289	CbGpPWpGaD
Vandetanib—LYN—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000277	0.00279	CbGpPWpGaD
Vandetanib—LCK—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000274	0.00277	CbGpPWpGaD
Vandetanib—FYN—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000273	0.00275	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—IFNA1—vaginal cancer	0.000273	0.00275	CbGpPWpGaD
Vandetanib—SRC—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000243	0.00245	CbGpPWpGaD
Vandetanib—VEGFA—Hemostasis—IL2—vaginal cancer	0.00024	0.00241	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—IL2—vaginal cancer	0.000231	0.00233	CbGpPWpGaD
Vandetanib—LCK—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000227	0.00229	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IFNA1—vaginal cancer	0.000224	0.00225	CbGpPWpGaD
Vandetanib—LYN—Immune System—IFNA1—vaginal cancer	0.000219	0.00221	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IFNA1—vaginal cancer	0.000218	0.0022	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—IL2—vaginal cancer	0.000218	0.00219	CbGpPWpGaD
Vandetanib—FYN—Immune System—IFNA1—vaginal cancer	0.000215	0.00217	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—IFNA1—vaginal cancer	0.000204	0.00206	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—IL2—vaginal cancer	0.000199	0.00201	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IFNA1—vaginal cancer	0.000186	0.00188	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—IL2—vaginal cancer	0.000182	0.00183	CbGpPWpGaD
Vandetanib—LCK—Immune System—IFNA1—vaginal cancer	0.000179	0.00181	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—IL2—vaginal cancer	0.000173	0.00175	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—IL2—vaginal cancer	0.000173	0.00174	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—IL2—vaginal cancer	0.000172	0.00173	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—IL2—vaginal cancer	0.00017	0.00171	CbGpPWpGaD
Vandetanib—ALB—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000164	0.00165	CbGpPWpGaD
Vandetanib—SRC—Immune System—IFNA1—vaginal cancer	0.000159	0.0016	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—IL2—vaginal cancer	0.000157	0.00158	CbGpPWpGaD
Vandetanib—BLK—Immune System—IL2—vaginal cancer	0.000151	0.00152	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—IL2—vaginal cancer	0.000151	0.00152	CbGpPWpGaD
Vandetanib—FGR—Immune System—IL2—vaginal cancer	0.00015	0.00152	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—IL2—vaginal cancer	0.000141	0.00143	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IL2—vaginal cancer	0.000138	0.00139	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—IL2—vaginal cancer	0.000125	0.00126	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL2—vaginal cancer	0.000121	0.00122	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL2—vaginal cancer	0.000101	0.00102	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL2—vaginal cancer	9.27e-05	0.000935	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL2—vaginal cancer	9.24e-05	0.000931	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL2—vaginal cancer	9.05e-05	0.000912	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL2—vaginal cancer	9.04e-05	0.000911	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL2—vaginal cancer	9.01e-05	0.000908	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL2—vaginal cancer	8.94e-05	0.000901	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL2—vaginal cancer	8.91e-05	0.000898	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—IL2—vaginal cancer	8.46e-05	0.000852	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL2—vaginal cancer	8.42e-05	0.000849	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL2—vaginal cancer	8.12e-05	0.000819	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL2—vaginal cancer	7.85e-05	0.000791	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL2—vaginal cancer	7.7e-05	0.000776	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL2—vaginal cancer	7.42e-05	0.000748	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL2—vaginal cancer	6.57e-05	0.000662	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL2—vaginal cancer	5.98e-05	0.000602	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL2—vaginal cancer	5.85e-05	0.00059	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL2—vaginal cancer	5.76e-05	0.00058	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL2—vaginal cancer	4.98e-05	0.000502	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL2—vaginal cancer	4.8e-05	0.000483	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL2—vaginal cancer	4.25e-05	0.000428	CbGpPWpGaD
